173 results
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
26 Feb 24
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
7:05am
of 2022.
Research and development (R&D) expenses for the fourth quarter of 2023 decreased to $70.1 million from $73.2 million in the fourth quarter of 2022 … net loss for the fourth quarter of 2023 was $56.4 million, or $0.28 per share when excluding one-time costs associated with the R&D restructuring
8-K
EX-99.1
BCRX
Biocryst Pharmaceuticals Inc.
8 Jan 24
Results of Operations and Financial Condition
7:02am
-mediated diseases and maximize the commercial potential of the program. As a result, the company has reduced the size of its R&D organization and accelerated … expects that R&D expenses in 2024 will be reduced by $20 million versus 2023. This represents a $45 million to $55 million reduction from the 2024 R&D expense
8-K
xrklp2raf91bg
3 Nov 23
Regulation FD Disclosure
12:16pm
8-K
EX-99.1
l3f u02w0fr
3 Nov 23
Regulation FD Disclosure
12:16pm
8-K
EX-99.1
dt67w 87enp3i
3 Nov 23
Regulation FD Disclosure
12:14pm
8-K
EX-99.1
kfwub
2 Nov 23
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
EX-99.1
go12yeff eex
3 Aug 23
BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
7:04am
8-K
EX-99.1
ba66 fb3de5
3 May 23
BioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
7:08am
8-K
EX-99.1
i6b9mkanduurj
15 Dec 22
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
7:03am
8-K
EX-99.1
s5gu8s
5 May 22
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
7:05am